1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd.

0.48
EUR
+0.00
(-0.83%)
2.99BMarket Cap
Mar 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.56
14.06
16.65
25.58
19.1
23.27
29.23
22.63
30.81
34.73
38.95
41.01
42.91
- -
Basic EPS, GAAP
0.26
0.27
0.32
0.46
0.39
0.49
0.47
0.37
0.49
0.56
0.61
0.53
0.64
- -
Free Cash Flow per Basic Share
0.11
0.1
0.41
0.37
0.32
0.77
0.87
0.68
1.26
1.29
1.98
2.28
2.69
- -
Dividend per Share
- -
- -
- -
- -
0.06
0.08
0.12
0.08
0.1
0.13
0.14
0.24
0.12
- -
Book Value per Share
1.78
2.13
2.56
4.8
4.64
4.82
5.82
5.25
6.58
6.93
7.32
7.68
8.18
8.18
Tangible Book Value per Share
-0.28
-0.12
-0.08
1.8
1.54
1.46
2.18
2.08
2.17
2.48
2.62
2.76
2.52
2.52
Basic Weighted Avg Shares
6,173
6,173
6,173
4,912
6,285
6,285
6,285
6,283
6,283
6,283
6,283
6,283
6,283
6,283
Sales/Revenue/Turnover
71,349
86,815
102,771
125,646
120,065
146,261
183,669
142,163
193,564
218,183
244,704
257,673
269,574
- -
Operating Margin (%)
7.49
6.85
6.96
6.62
6.66
7.01
5.08
5.65
5.3
5.66
5.13
5.15
5.21
- -
Depreciation Expense
729
865
944
1,022
1,090
1,246
2,124
1,734
2,307
2,558
3,164
3,357
4,082
- -
Net Income, GAAP
1,610
1,692
1,998
2,262
2,424
3,067
2,952
2,339
3,081
3,500
3,854
3,351
4,045
- -
Effective Tax Rate (%)
21.1
20.67
24.45
25.79
19.99
17.54
23.22
24.76
20.94
20.37
21.31
23.12
18.17
- -
Profit Margin (%)
2.26
1.95
1.94
1.8
2.02
2.1
1.61
1.65
1.59
1.6
1.58
1.3
1.5
- -
Working Capital
6,040
12,026
11,663
18,295
14,937
18,434
23,600
17,371
28,851
30,489
44,335
53,624
59,498
59,498
LT Debt
6,744
10,816
9,033
5,119
2,396
7,826
9,771
2,244
6,633
9,812
15,937
23,632
22,077
22,077
Total Equity
19,918
23,759
27,939
43,539
43,937
46,625
62,508
56,766
77,659
80,557
92,975
98,087
117,456
117,456
Return on Invested Capital (%)
- -
11.13
11.8
10.47
9.42
10.72
7.91
6.05
7.19
7.5
6.33
5.81
5.9
- -
Return on Capital (%)
- -
2.21
1.61
1.37
1.96
2.78
4.19
2.75
2.36
1.83
1.28
0.03
0.05
- -
Return on Common Equity (%)
- -
14.05
13.83
9.85
8.17
10.32
8.83
6.73
8.29
8.24
8.61
7.11
8.12
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
45,373
56,405
50,329
LT Borrowings
22,864
25,582
21,347
LT Finance Leases
768
764
730
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,283
6,283
6,283
Market Capitalization
31,983
29,436
24,580

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
185,846
203,069
201,707
Cash, Cash Equivalents & STI
25,648
26,805
27,913
Accounts Receivable, Net
100,548
110,237
105,779
Inventories
37,053
41,936
43,271
Total Current Liabilities
132,222
144,326
142,209
Payables & Accruals
- -
- -
- -
ST Debt
45,373
56,405
50,329
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.89%
16.24%
19.75%
Free Cash Flow
29.11%
35.15%
18.11%
Net Income, GAAP
8.55%
12.63%
20.73%
Sales/Revenue/Turnover
11.36%
14.19%
4.62%
Total Cash Common Dividend
- -
17.48%
-47.68%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
244,704
2024
- -
- -
257,673
2025
- -
- -
269,574

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.61
2024
- -
- -
0.53
2025
- -
- -
0.64

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.14
2024
- -
- -
0.24
2025
- -
- -
0.12

Company Description

Company Profile APIChatGPT
CEO
Xiaosong Bai
Full Time Employees
85,600
Sector
Health technology
Industry
Pharmaceuticals: major
Address
China Resources Building Hong Kong Hong Kong
IPO Date
Oct 28, 2016
Website
crpharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China Resources Pharmaceutical Group Limited (Ticker: 3320.HK) is a leading pharmaceutical conglomerate headquartered in Hong Kong, founded in 1998. It operates primarily in the pharmaceutical manufacturing and distribution industry, offering a comprehensive portfolio of products and services that includes active pharmaceutical ingredients; finished dosage forms such as tablets, capsules, and injectables; Chinese patent medicines; health supplements; and medical devices. The company also engages in pharmaceutical distribution, retail pharmacy chains, and healthcare services across Mainland China and other regions. The company maintains extensive operations in Mainland China, with a strong presence in both the upstream pharmaceutical manufacturing sector and the downstream pharmaceutical distribution and retail markets. China Resources Pharmaceutical caters to a broad customer base including hospitals, pharmacies, healthcare institutions, and consumers seeking traditional and modern pharmaceutical products. In recent years, China Resources Pharmaceutical has pursued strategic expansions and business enhancements, including partnerships to strengthen its pharmaceutical supply chain, investments in biotechnology innovation, and the launch of new healthcare products. Notably, it has expanded its capabilities in innovative drug development as well as increasing its footprint in pharmaceutical distribution networks. The company continues to leverage its integrated business model to enhance operational efficiency and market competitiveness within China’s evolving healthcare landscape. China Resources Pharmaceutical Group Limited is a subsidiary under China Resources Holdings Company, benefiting from the parent group's broad industrial and financial support. The company remains committed to innovation-driven growth and enhancing healthcare accessibility through its diversified product lines and service offerings.